Commentary: Despite reports of catastrophic complications, why recombinant human bone morphogenetic protein-2 should be available for use in anterior cervical spine surgery

Spine Journal

Volumn 12, Issue 10, 2012, Pages 900-901

  Riew, K Daniel ^a   Carragee, Eugene J ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

DRUG EXPOSURE; DRUG USE; HUMAN; OSSIFICATION; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; RISK BENEFIT ANALYSIS; SPINE FUSION; SPINE SURGERY; SWELLING; WOUND COMPLICATION;

EID: 84870260044     PISSN: 15299430     EISSN: 18781632     Source Type: Journal    
DOI: 10.1016/j.spinee.2012.10.010     Document Type: Note

References (4)

1. E.J. Woo Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience database Spine J 12 2012 894 899
2. J. Even, M. Eskander, and J. Kang Bone morphogenetic protein in spine surgery: current and future uses J Am Acad Orthop Surg 20 2012 547 552
3. Food and Drug Adminstration. Food and Drug Administration Executive Summary for P050036 Medtronic's AMPLIFYTM rhBMP-2 Matrix Orthopaedic and Rehabilitation Devices Advisory Panel. 2010; Available at: http://www.fda.gov/ downloads/advisorycommittees/committeesmeetingmaterials/medicaldevices/ medicaldevicesadvisorycommittee/orthopaedicandrehabilitationdevicespanel/ ucm220079.pdf. Accessed October 10, 2012.
4. W.M. Lee Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure Hepatology 40 2004 6 9